Norfloxacinの副鼻腔炎に対する臨床効果

概要

論文の詳細を見る
Norfloxacin (NFLX) 600 mg/day t. i. d., was administered orally to 104 patients of acute paranasal sinusitis (APS) and acute exacerbation of chronic paranasal sinusitis (AECPS). The following results were obtained: (1) The clinical efficacy was evaluated in 51 cases of APS and 47 cases of AECPS.(2) The overall efficacy rate (cases of excellent and good responses) as judged by the attending physician) was 78.6 % of all patients. The efficacy rate was 84.3 % in APS and 72.3 % in AECPS.(3) The overall efficacy rate was 79.6 % as judged by a committee. The efficacy rate were 88.2 % in APS and 70.2 % in AECPS.(4) Bacteriological efficacy rate was 81.5 % (eliminated and replaced). The efficacy rate was 88.9 % in APS and 80.6 % in AECPS.(5) Improvement rates in X-ray fidings were evaluated in 68 cases. The rate of excellent plus good results was 55.9 %, and that of excellent, good plus moderate results was 80.9 %. These two rates were respectively 61.3 % and 83.9 % in APS, and 51.4 % and 78.4 % in AECPS.(6) Side effect was observed in 1 (1 %) of 100 cases. No abnormal laboratory findings were found. From these results, NFLX is judged as a useful drug in the treatment of the paranasal sinusitis.
耳鼻と臨床会の論文